Opportunities and Challenges for In Silico Drug Discovery at Delta Opioid Receptors.

ABSTRACT: The delta opioid receptor is a Gi-protein-coupled receptor (GPCR) with a broad expression pattern both in the central nervous system and the body. The receptor has been investigated as a potential target for a multitude of significant diseases including migraine, alcohol use disorder, ischemia, and neurodegenerative diseases. Despite multiple attempts, delta opioid receptor-selective molecules have not been translated into the clinic. Yet, the therapeutic promise of the delta opioid receptor remains and thus there is a need to identify novel delta opioid receptor ligands to be optimized and selected for clinical trials. Here, we highlight recent developments involving the delta opioid receptor, the closely related mu and kappa opioid receptors, and in the broader area of the GPCR drug disc

SUBMITTER: Meqbil YJ 

PROVIDER: S-EPMC9324648 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature